Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anaptysbio Inc (NQ: ANAB )

34.45 -0.01 (-0.03%)
Official Closing Price Updated: 4:15 PM EDT, Jul 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 400,204
Open 34.64
Bid (Size) 32.32 (1)
Ask (Size) 55.16 (2)
Prev. Close 34.46
Today's Range 34.11 - 36.21
52wk Range 13.36 - 36.21
Shares Outstanding 27,433,359
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Analyst Landscape: 7 Takes On AnaptysBio
Via Benzinga
ANAB Stock Earnings: AnaptysBio Misses EPS, Beats Revenue for Q1 2024
ANAB stock results show that AnaptysBio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+58.76%
+58.76%
1 Month
+50.50%
+50.50%
3 Month
+73.73%
+73.73%
6 Month
+45.42%
+45.42%
1 Year
+81.32%
+81.32%

More News

Read More
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
From AnaptysBio, Inc.
Via GlobeNewswire
Unveiling 4 Analyst Insights On AnaptysBio
Via Benzinga
BTIG Research Predicts Over 118% Rally for These 3 Stocks
Via InvestorPlace
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
Via The Motley Fool
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers
Via Benzinga
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Named a BioSpace 2024 Best Places to Work Winner
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Participation in November Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
From AnaptysBio, Inc.
Via GlobeNewswire
Why Is Skin Disease Focused AnaptysBio Stock Trading Higher Today?
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
From AnaptysBio, Inc.
Via GlobeNewswire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Via MarketBeat
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
From AnaptysBio, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.